

Matthew S Davids

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9349961/publications.pdf>

Version: 2024-02-01

169
papers

9,346
citations

76322
40
h-index

40976
93
g-index

169
all docs

169
docs citations

169
times ranked

10212
citing authors

#	ARTICLE	IF	CITATIONS
1	Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor–induced dermatologic adverse events. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 1271-1281.	1.2	18
2	Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 32.e1-32.e10.	1.2	7
3	Venetoclax in Previously Treated Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 63-71.	1.6	53
4	Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	8
5	Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. <i>Blood</i> , 2022, 139, 686-689.	1.4	29
6	A multicenter, retrospective study of accelerated venetoclax ramp–up in patients with relapsed/refractory chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	3
7	Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. <i>Haematologica</i> , 2022, 107, 984-987.	3.5	19
8	Idelalisib in indolent NHL – has it finally found its niche?. <i>Leukemia and Lymphoma</i> , 2021, 62, 1029-1030.	1.3	0
9	miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. <i>Blood</i> , 2021, 137, 2481-2494.	1.4	37
10	A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. <i>Leukemia</i> , 2021, 35, 1064-1072.	7.2	25
11	Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 2251-2256.	3.5	7
12	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , 2021, 137, 3212-3217.	1.4	24
13	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet, The</i> , 2021, 397, 892-901.	13.7	260
14	Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy. <i>EJHaem</i> , 2021, 2, 266-271.	1.0	3
15	Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2342-2351.	1.3	8
16	Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. <i>Clinical Cancer Research</i> , 2021, 27, 4690-4695.	7.0	38
17	Twists and turns from –tumor in tumor–profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a006089.	1.2	0
18	BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. <i>Blood</i> , 2021, 137, 3495-3506.	1.4	22

#	ARTICLE	IF	CITATIONS
19	Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. <i>Cancer Discovery</i> , 2021, 11, 3048-3063.	9.4	31
20	IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K γ inhibitor idelalisib. <i>Haematologica</i> , 2021, 106, 2995-2999.	3.5	14
21	Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. <i>Haematologica</i> , 2021, 106, 3219-3222.	3.5	15
22	The redox-senescence axis and its therapeutic targeting. <i>Redox Biology</i> , 2021, 45, 102032.	9.0	34
23	Integrated safety analysis of umbralisib, a dual PI3K γ /CK1 β inhibitor, in relapsed/refractory lymphoid malignancies. <i>Blood Advances</i> , 2021, 5, 5332-5343.	5.2	13
24	Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1391-1402.	10.7	53
25	Targeting constitutively active <sc>STAT3</sc> in chronic lymphocytic leukemia: A clinical trial of the <sc>STAT3</sc> inhibitor pyrimethamine with pharmacodynamic analyses. <i>American Journal of Hematology</i> , 2021, 96, E95-E98.	4.1	17
26	A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. <i>Haematologica</i> , 2021, 106, 651-654.	3.5	4
27	Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1532-1544.	0.9	8
28	A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, , .	7.2	14
29	Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 2633-2633.	1.4	1
30	A Phase I Trial of PI3K δ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL). <i>Blood</i> , 2021, 138, 3558-3558.	1.4	3
31	Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. <i>Blood</i> , 2021, 138, 1553-1553.	1.4	2
32	ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 2634-2634.	1.4	4
33	Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 640-640.	1.4	4
34	BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress). <i>Blood</i> , 2021, 138, 3742-3742.	1.4	4
35	Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2021, 138, 391-391.	1.4	8
36	Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab. <i>Blood</i> , 2021, 138, 1201-1201.	1.4	3

#	ARTICLE	IF	CITATIONS
37	Highlights in chronic lymphocytic leukemia from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary. Clinical Advances in Hematology and Oncology, 2021, 19 Suppl 4, 21-23.	0.3	0
38	Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis. Clinical Therapeutics, 2020, 42, 1955-1974.e15.	2.5	15
39	Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism. Nucleic Acids Research, 2020, 48, 12727-12745.	14.5	27
40	Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect Â® CLL Registry. EJHaem, 2020, 1, 188-198.	1.0	2
41	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Advances, 2020, 4, 3977-3989.	5.2	55
42	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood, 2020, 135, 2182-2191.	1.4	62
43	Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States. Pharmacoeconomics, 2020, 38, 941-951.	3.3	11
44	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Advances, 2020, 4, 858-867.	5.2	40
45	Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet, The, 2020, 395, 1078-1088.	13.7	302
46	Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clinical Cancer Research, 2020, 26, 2096-2103.	7.0	31
47	Systematic literature review of the global burden of illness of mantle cell lymphoma. Current Medical Research and Opinion, 2020, 36, 843-852.	1.9	3
48	Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. Blood Advances, 2020, 4, 1458-1463.	5.2	28
49	Acalabrutinib for the initial treatment of chronic lymphocytic leukaemia. Lancet, The, 2020, 395, 1234-1236.	13.7	1
50	Breaking through BCL-2 inhibition in CLL. Blood, 2020, 135, 709-711.	1.4	6
51	LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study. Blood, 2020, 136, 35-37.	1.4	16
52	Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings. Blood, 2020, 136, 15-17.	1.4	9
53	Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome. Blood, 2020, 136, 46-47.	1.4	13
54	Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 20-21.	1.4	16

#	ARTICLE	IF	CITATIONS
55	A Multicenter, Retrospective Study of Accelerated Venetoclax Ramp-up in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 51-52.	1.4	4
56	Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement. <i>Blood</i> , 2020, 136, 29-30.	1.4	0
57	Local and Systemic Effects of Immune Checkpoint Blockade on Relapsed Myeloid Malignancies Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 34-35.	1.4	1
58	Genetic Determinants and Evolutionary History of Richter's Syndrome. <i>Blood</i> , 2020, 136, 47-48.	1.4	3
59	Improving Physician-Patient Decision Making for Treatment of Chronic Lymphocytic Leukemia with BTK Inhibition. <i>Blood</i> , 2020, 136, 20-20.	1.4	0
60	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	1.4	2
61	CCR2 Expression Signature Can Classify and Predict Outcome in a Subpopulation of Chronic Lymphocytic Leukemia (CLL) Patients. <i>Blood</i> , 2020, 136, 13-14.	1.4	0
62	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 22-23.	1.4	4
63	Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. <i>Blood</i> , 2020, 136, 37-38.	1.4	1
64	Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib. <i>Leukemia and Lymphoma</i> , 2019, 60, 527-530.	1.3	14
65	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e419-e428.	4.6	60
66	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. <i>Blood</i> , 2019, 134, 1132-1143.	1.4	81
67	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	7.0	10
68	Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. <i>Cancer Cell</i> , 2019, 36, 369-384.e13.	16.8	224
69	Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition. <i>JAAD Case Reports</i> , 2019, 5, 401-405.	0.8	10
70	Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. <i>Blood</i> , 2019, 134, 111-122.	1.4	145
71	BCL-2 Inhibitors, Present and Future. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 401-409.	2.0	25
72	Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1b study. <i>Lancet Haematology</i> , 2019, 6, e38-e47.	4.6	98

#	ARTICLE	IF	CITATIONS
73	Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cyto reduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1312-1315.	1.3	3
74	Early Adoption and Outcomes of Ibrutinib As Treatment for Older Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Study. <i>Blood</i> , 2019, 134, 265-265.	1.4	4
75	Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na ^{ve} Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven). <i>Blood</i> , 2019, 134, 4320-4320.	1.4	7
76	Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States. <i>Blood</i> , 2019, 134, 4741-4741.	1.4	8
77	High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR). <i>Blood</i> , 2019, 134, 4291-4291.	1.4	1
78	Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3965-3965.	1.4	1
79	Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vencabrutinib, in B-Cell Malignancies. <i>Blood</i> , 2019, 134, 3041-3041.	1.4	23
80	Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax. <i>Blood</i> , 2019, 134, 807-807.	1.4	2
81	A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL. <i>Blood</i> , 2019, 134, 1763-1763.	1.4	6
82	Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 32-32.	1.4	28
83	Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na ^{ve} Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study. <i>Blood</i> , 2019, 134, 2015-2015.	1.4	3
84	An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 4716-4716.	1.4	1
85	Risk of hepatitis B virus reactivation in patients treated with ibrutinib. <i>Blood</i> , 2018, 131, 1987-1989.	1.4	42
86	Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation. <i>Cancer Imaging</i> , 2018, 18, 13.	2.8	3
87	Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2018, 131, 1073-1080.	1.4	26
88	Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. <i>Blood</i> , 2018, 131, 1704-1711.	1.4	122
89	A complex case of ibrutinib treatment for a <sc>CLL</sc> patient on haemodialysis. <i>British Journal of Haematology</i> , 2018, 181, 854-857.	2.5	4
90	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 65-75.	10.7	314

#	ARTICLE	IF	CITATIONS
91	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1973-1980.	1.6	257
92	The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. <i>Blood</i> , 2018, 132, 2446-2455.	1.4	261
93	A new triple threat to CLL. <i>Blood</i> , 2018, 132, 1547-1548.	1.4	0
94	The rise of apoptosis: targeting apoptosis in hematologic malignancies. <i>Blood</i> , 2018, 132, 1248-1264.	1.4	107
95	Statins enhance efficacy of venetoclax in blood cancers. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	61
96	Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2018, 24, 4371-4379.	7.0	127
97	Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. <i>JCI Insight</i> , 2018, 3, .	5.0	39
98	The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax. <i>Blood</i> , 2018, 132, 4393-4393.	1.4	7
99	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. <i>Blood</i> , 2018, 132, 145-145.	1.4	5
100	Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2888-2888.	1.4	22
101	Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study. <i>Blood</i> , 2018, 132, 1856-1856.	1.4	2
102	The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study. <i>Blood</i> , 2018, 132, 3140-3140.	1.4	2
103	A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT). <i>Blood</i> , 2018, 132, 705-705.	1.4	10
104	Genetic Determinants of Venetoclax Resistance in Lymphoid Malignancies. <i>Blood</i> , 2018, 132, 893-893.	1.4	4
105	Characterization of the Long-Term Efficacy and Safety of Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on Treatment for > 2 Years across 4 Clinical Studies. <i>Blood</i> , 2018, 132, 3146-3146.	1.4	1
106	Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration. <i>Blood</i> , 2018, 132, 1648-1648.	1.4	0
107	Systematic Reviews of the Clinical Efficacy and Safety of First-Line Treatments for Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 5868-5868.	1.4	0
108	Systematic Literature Review of the Cost-Effectiveness of Treatments, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 5848-5848.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. <i>Lancet Oncology</i> , 2017, 18, 230-240.	10.7	287
110	The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 11-19.	2.3	44
111	Venetoclax for the treatment of patients with chronic lymphocytic leukemia. <i>Future Oncology</i> , 2017, 13, 1223-1232.	2.4	7
112	Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. <i>European Journal of Heart Failure</i> , 2017, 19, 682-685.	7.1	39
113	IGHV mutational status testing in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 1393-1397.	4.1	47
114	Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. <i>Cancer Discovery</i> , 2017, 7, 156-164.	9.4	164
115	Targeting BCL-2 in B-cell lymphomas. <i>Blood</i> , 2017, 130, 1081-1088.	1.4	58
116	Safety profiles of novel agent therapies in CLL. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 354-357.	2.5	1
117	How should we sequence and combine novel therapies in CLL?. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 346-353.	2.5	18
118	Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 826-833.	1.6	596
119	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients Who Underwent Reduced Intensity Conditioning Allogeneic HCT: A CIBMTR Report. <i>Blood</i> , 2017, 130, 667-667.	1.4	2
120	Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd couple. <i>BJR case Reports</i> , 2016, 2, 20150271.	0.2	3
121	FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-methylated chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016, 91, 978-983.	4.1	14
122	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	16.8	227
123	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. <i>Blood</i> , 2016, 127, 3215-3224.	1.4	242
124	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , 2016, 128, 195-203.	1.4	259
125	Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. <i>Blood</i> , 2016, 128, 1609-1613.	1.4	85
126	Ipilimumab for Patients with Relapse after Allogeneic Transplantation. <i>New England Journal of Medicine</i> , 2016, 375, 143-153.	27.0	488

#	ARTICLE	IF	CITATIONS
127	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. <i>Nature Communications</i> , 2016, 7, 11589.	12.8	285
128	A phase 2 study of Rituximab+ Bendamustine and Rituximab+ Cytarabine for transplant-eligible patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 89-95.	2.5	51
129	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 311-322.	27.0	1,532
130	Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 3230-3230.	1.4	12
131	Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. <i>Blood</i> , 2016, 128, 3243-3243.	1.4	15
132	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Is Highly BCL-2 Dependent and Sensitive to Venetoclax. <i>Blood</i> , 2016, 128, 4045-4045.	1.4	1
133	Acalabrutinib Increases Mitochondrial Priming and Enhances Venetoclax Sensitivity in CLL Cells. <i>Blood</i> , 2016, 128, 4346-4346.	1.4	2
134	Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4395-4395.	1.4	7
135	Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. <i>Blood</i> , 2016, 128, 637-637.	1.4	48
136	TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. <i>Blood</i> , 2016, 128, 641-641.	1.4	10
137	The BCL-2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 ^{hi} Wild-type and CXCR4 ^{hi} WHIM ^{hi} mutated Waldenstrom macroglobulinaemia cells. <i>British Journal of Haematology</i> , 2015, 170, 134-138.	2.5	63
138	Controversial fluorescence <i>in situ</i> hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. <i>British Journal of Haematology</i> , 2015, 170, 694-703.	2.5	19
139	BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis. <i>Clinical Cancer Research</i> , 2015, 21, 5021-5029.	7.0	76
140	The Evolving Role of Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 18-27.	2.3	2
141	Ibrutinib Therapy Increases BCL-2 Dependence and Enhances Sensitivity to Venetoclax in CLL. <i>Blood</i> , 2015, 126, 490-490.	1.4	15
142	Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. <i>Future Oncology</i> , 2014, 10, 957-967.	2.4	136
143	Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma?. <i>Leukemia and Lymphoma</i> , 2014, 55, 2675-2677.	1.3	2
144	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1499-1508.	3.5	15

#	ARTICLE	IF	CITATIONS
145	Association of Advanced Leukemic Stage and Skin Cancer Tumor Stage With Poor Skin Cancer Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Dermatology, 2014, 150, 280.	4.1	83
146	Boldly Targeting Kinases without mutations. Blood, 2014, 123, 1119-1121.	1.4	6
147	Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood, 2014, 124, 325-325.	1.4	32
148	Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clinical Advances in Hematology and Oncology, 2014, 12, 224-9.	0.3	25
149	Phosphoinositide 3-Kinase Inhibition in Chronic Lymphocytic Leukemia. Hematology/Oncology Clinics of North America, 2013, 27, 329-339.	2.2	8
150	Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leukemia and Lymphoma, 2013, 54, 1823-1825.	1.3	23
151	ABT-199: Taking Dead Aim at BCL-2. Cancer Cell, 2013, 23, 139-141.	16.8	83
152	The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients. Blood, 2013, 122, 1789-1789.	1.4	32
153	Update On The Safety and Efficacy Of The Pan Class I PI3K Inhibitor SAR245408 (XL147) In Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients. Blood, 2013, 122, 4170-4170.	1.4	8
154	Therapeutic Targeting of the Bcl2 Family. Blood, 2013, 122, SCI-42-SCI-42.	1.4	0
155	Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood, 2012, 120, 3501-3509.	1.4	117
156	Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 2362-2370.	1.3	71
157	Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer. Journal of Clinical Oncology, 2012, 30, 3127-3135.	1.6	236
158	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study. Blood, 2012, 120, 304-304.	1.4	18
159	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study. Blood, 2012, 120, 3923-3923.	1.4	3
160	Cell Trafficking in Chronic Lymphocytic Leukemia. Open Journal of Hematology, 2012, 3, 1.	0.4	56
161	Prior Treatment with Chemotherapy Is Associated with Poor Outcomes of High Risk Skin Cancers in Patients with Chronic Lymphocytic Leukemia. Blood, 2012, 120, 3920-3920.	1.4	0
162	Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era. Blood, 2012, 120, 1980-1980.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma. Blood, 2011, 118, 2683-2683.	1.4	3
164	BH3 Profiling Demonstrates That Restoration of Apoptotic Priming Contributes to Increased Sensitivity to PI3K Inhibition in Stroma-Exposed Chronic Lymphocytic Leukemia Cells. Blood, 2011, 118, 974-974.	1.4	2
165	Rearrangement of 14q32 in the Absence of t(14;18) Is Associated with Short Time to First Treatment in Chronic Lymphocytic Leukemia. Blood, 2011, 118, 1438-1438.	1.4	0
166	MEDICAL MANAGEMENT OF RADIATION VICTIMS IN THE UNITED STATES. Health Physics, 2010, 98, 833-837.	0.5	6
167	The molecular pathogenesis of myelodysplastic syndromes. Cancer Biology and Therapy, 2010, 10, 309-319.	3.4	38
168	Assessing Surge Capacity for Radiation Victims with Marrow Toxicity. Biology of Blood and Marrow Transplantation, 2010, 16, 1436-1441.	2.0	9
169	BH3 Profiling Demonstrates Decreased Mitochondrial Priming for Apoptosis In Primary CLL Cells Exposed to Stroma. Blood, 2010, 116, 692-692.	1.4	0